19 results
8-K
EX-1.1
ACXP
Acurx Pharmaceuticals, Inc.
15 Nov 23
Entry into a Material Definitive Agreement
5:02pm
11 hereunder, will pay the following expenses all incident to the performance of its obligations hereunder, including, but not limited to, expenses
424B3
erq34e5nf6k1
13 Jul 23
Prospectus supplement
4:32pm
8-K
EX-10.1
gjc1grwzbxsju
17 May 23
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
4:19pm
8-K
EX-1.1
9jyn8e awtonryk21
17 May 23
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
4:19pm
424B3
p3y igmhd4v3nzlt
23 Sep 22
Prospectus supplement
8:19am
8-K
EX-10.1
fp1bpvqvw1n0a
25 Jul 22
Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering
8:46am
8-K
EX-1.1
o1f 17vkah55g1xhi
25 Jul 22
Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering
8:46am
S-1
EX-10.10
rduz641s
27 May 21
IPO registration
12:00am
S-1
EX-10.5
ix3ieow
27 May 21
IPO registration
12:00am
S-1
EX-1.1
dej j2tkyrv7v
27 May 21
IPO registration
12:00am
DRS/A
EX-10.5
co2k8
10 May 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.10
w50x42fz
10 May 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next